EP1070122A4 - Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery - Google Patents
Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codeliveryInfo
- Publication number
- EP1070122A4 EP1070122A4 EP99913854A EP99913854A EP1070122A4 EP 1070122 A4 EP1070122 A4 EP 1070122A4 EP 99913854 A EP99913854 A EP 99913854A EP 99913854 A EP99913854 A EP 99913854A EP 1070122 A4 EP1070122 A4 EP 1070122A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- apoptic
- induction
- codelivery
- cytotoxic
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7754198P | 1998-03-11 | 1998-03-11 | |
US77541P | 1998-03-11 | ||
PCT/US1999/005359 WO1999046371A2 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1070122A2 EP1070122A2 (en) | 2001-01-24 |
EP1070122A4 true EP1070122A4 (en) | 2004-11-10 |
Family
ID=22138678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99913854A Withdrawn EP1070122A4 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1070122A4 (en) |
AU (1) | AU762493B2 (en) |
CA (1) | CA2322663A1 (en) |
WO (1) | WO1999046371A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2404235C (en) * | 2000-03-24 | 2010-09-21 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
AU2001265219A1 (en) | 2000-05-31 | 2001-12-11 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
DE60142050D1 (en) * | 2000-06-02 | 2010-06-17 | Takeda Pharmaceutical | PROMOTER OF PROLIFERATION AND INHIBITOR OF APOPTOSIS OF PANCREATIC LANGERHANS BETA CELLS AND SCREENING OF PROTECTIVE COMPOUNDS FOR MEDICAMENTS |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
EP1207205A1 (en) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Adenoviral replicons |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
AU2002364364A1 (en) * | 2001-12-31 | 2003-07-24 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
JP4511108B2 (en) | 2002-05-31 | 2010-07-28 | オンコリクス インコーポレイテッド | Human prolactin antagonist-angiogenesis inhibitor fusion protein |
CN100361710C (en) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
MA50509A (en) | 2017-11-03 | 2021-06-02 | Amgen Inc | APJ RECEPTOR FUSED TRIAZOLE AGONISTS |
MA52487A (en) | 2018-05-01 | 2021-03-10 | Amgen Inc | PYRIMIDINONES SUBSTITUTED AS APJ RECEPTOR AGONISTS |
CN110174456B (en) * | 2019-06-11 | 2021-09-21 | 华润双鹤药业股份有限公司 | Method for measuring lung surfactant protein and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025507A2 (en) * | 1995-02-17 | 1996-08-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of preparation and use of recombinant adenoviral vectors |
WO1997040180A1 (en) * | 1996-04-20 | 1997-10-30 | Boehringer Ingelheim International Gmbh | Chicken embryo lethal orphan (celo) virus |
WO2000015648A1 (en) * | 1998-09-10 | 2000-03-23 | The Uab Research Foundation | Adenoviral vector encoding pro-apoptotic bax gene and uses thereof |
-
1999
- 1999-03-11 WO PCT/US1999/005359 patent/WO1999046371A2/en active IP Right Grant
- 1999-03-11 EP EP99913854A patent/EP1070122A4/en not_active Withdrawn
- 1999-03-11 AU AU31837/99A patent/AU762493B2/en not_active Ceased
- 1999-03-11 CA CA002322663A patent/CA2322663A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025507A2 (en) * | 1995-02-17 | 1996-08-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of preparation and use of recombinant adenoviral vectors |
WO1997040180A1 (en) * | 1996-04-20 | 1997-10-30 | Boehringer Ingelheim International Gmbh | Chicken embryo lethal orphan (celo) virus |
WO2000015648A1 (en) * | 1998-09-10 | 2000-03-23 | The Uab Research Foundation | Adenoviral vector encoding pro-apoptotic bax gene and uses thereof |
Non-Patent Citations (12)
Title |
---|
"RETROVIRAL BAX GENE TRANSFER FAILS TO SENSITIZE MALIGNANT GLIOMA CELLS TO CD95L-INDUCED APOPTOSIS AND CANCER CHEMOTHERAPY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, August 1998 (1998-08-01), pages 645 - 648, XP002922344, ISSN: 0020-7136 * |
BOISE L H ET AL: "BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL DEATH", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 74, 27 August 1993 (1993-08-27), pages 597 - 608, XP002018919, ISSN: 0092-8674 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SIMONIAN PHILIP L ET AL: "Bax homodimerization is not required for bax to accelerate chemotherapy-induced cell death", XP002282530, Database accession no. PREV199799338036 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ZHA HONGBIN ET AL: "Proapoptotic protein bax heterodimerizes with Bcl-2 and homodimerizes with bax via a novel domain (BH3) distinct from BH1 and BH2", XP002282529, Database accession no. PREV199698772776 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1993 (1993-12-01), KORSMEYER S J ET AL: "Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.", XP002282531, Database accession no. NLM8142617 * |
DERROW S ET AL: "Apoptosis induction by adenovirus-bclx-s: A rational strategy for bladder cancer gene therapy", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 38, no. 0, 1997, & EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN DIEGO, CALIFORNIA, USA; APRIL 12-16, 1997, pages 11, XP002282532, ISSN: 0197-016X * |
DERROW SOL ET AL: "Apoptosis induction by adenovirus-BCLX-S: A rational strategy for bladder cancer gene therapy", JOURNAL OF UROLOGY, vol. 157, no. 4 SUPPL., 1997, & 92ND ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; APRIL 12-17, 1997, pages 310, XP008031086, ISSN: 0022-5347 * |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 13, 1996, pages 7440 - 7444, ISSN: 0021-9258 * |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 50, 1996, pages 32073 - 32077, ISSN: 0021-9258 * |
KAGAWA S ET AL: "Induction of bax gene expression by adenoviral mediated gene codelivery", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 218, XP002282528, ISSN: 0197-016X * |
See also references of WO9946371A3 * |
SEMINARS IN CANCER BIOLOGY. DEC 1993, vol. 4, no. 6, December 1993 (1993-12-01), pages 327 - 332, ISSN: 1044-579X * |
Also Published As
Publication number | Publication date |
---|---|
AU762493B2 (en) | 2003-06-26 |
WO1999046371A3 (en) | 2000-08-24 |
CA2322663A1 (en) | 1999-09-16 |
WO1999046371A2 (en) | 1999-09-16 |
WO1999046371A9 (en) | 2000-02-17 |
AU3183799A (en) | 1999-09-27 |
EP1070122A2 (en) | 2001-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1070122A4 (en) | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
EP1017797A4 (en) | Non-primate lentiviral vectors and packaging systems | |
EP1315512A4 (en) | Adenoviral targeting and manipulation of immune system response using targeting peptides | |
EP1923467A3 (en) | Adenovirus vectors for gene therapy | |
HK1065074A1 (en) | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells | |
PL339735A1 (en) | Pappiloma virus capsomer vaccine compositions and methods of applying them | |
WO2001022990A3 (en) | Methods related to immunostimulatory nucleic acid-induced interferon | |
HUP9902310A2 (en) | Complementary adenoviral vector systems and cell lines | |
WO2000054813A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
WO2000073478A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration | |
WO2003023000A3 (en) | Linear dna fragments for gene expression | |
IL146125A0 (en) | Novel quinones as disease therapies | |
WO2001077080A3 (en) | Pyrazole compounds having anti proliferative activity | |
WO1999033998A3 (en) | Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof | |
WO1999064594A3 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
AU6583700A (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
DK0843731T3 (en) | Gene therapy adenovirus vectors | |
AU2164197A (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
AU3209300A (en) | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines | |
ZA200202413B (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression. | |
WO2001005435A3 (en) | Antisense therapy for hormone-regulated tumors | |
AU7794700A (en) | Recombinant adenoviruses preparation and adenovirus banks | |
EP1390388A4 (en) | Antisense modulation of interferon gamma receptor 1 expression | |
WO2000006735A8 (en) | Interferon alpha hybrids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001011 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 35/00 B Ipc: 7A 61K 48/00 B Ipc: 7C 12N 15/86 B Ipc: 7A 01N 43/04 B Ipc: 7C 12N 15/00 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040922 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROTH, JACK, A. Inventor name: JI, LI Inventor name: SARKISS, MONA, G. Inventor name: BRUCKHEIMER, ELIZABETH, M. Inventor name: FANG, BINGLIANG Inventor name: SWISHER, STEPHEN, G. Inventor name: MCDONNELL, TIMOTHY, J. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROTH, JACK, A. Inventor name: JI, LI Inventor name: SARKISS, MONA, G. Inventor name: BRUCKHEIMER, ELIZABETH, M. Inventor name: FANG, BINGLIANG Inventor name: SWISHER, STEPHEN, G. Inventor name: MCDONNELL, TIMOTHY, J. |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20070515BHEP Ipc: A61K 48/00 20060101ALI20070515BHEP Ipc: C12N 15/861 20060101ALI20070515BHEP Ipc: C12N 15/86 20060101ALI20070515BHEP Ipc: A01N 43/04 20060101ALI20070515BHEP Ipc: C12N 15/00 20060101AFI20070515BHEP |
|
RTI1 | Title (correction) |
Free format text: ADENOVIRUS FOR THE INDUCTION OF APOPTIC GENE EXPRESSION |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROTH, JACK, A. Inventor name: JI, LI Inventor name: SARKISS, MONA, G. Inventor name: BRUCKHEIMER, ELIZABETH, M. Inventor name: FANG, BINGLIANG Inventor name: SWISHER, STEPHEN, G. Inventor name: MCDONNELL, TIMOTHY, J. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081001 |